Related references
Note: Only part of the references are listed.The Hepatic Mitochondrial Pyruvate Carrier as a Regulator of Systemic Metabolism and a Therapeutic Target for Treating Metabolic Disease
Kyle S. McCommis et al.
BIOMOLECULES (2023)
Significant Dose-Response Association of Physical Activity and Diet Quality With Mortality in Adults With Suspected NAFLD in a Population Study
Eduardo Vilar-Gomez et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2023)
High-quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population
Eduardo Vilar-Gomez et al.
HEPATOLOGY (2022)
Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD
Elizabeth M. Brunt et al.
JOURNAL OF HEPATOLOGY (2022)
Saroglitazar, a PPAR-α/γ Agonist, for Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Double-Blind Phase 2 Trial
Manas Kumar Panigrahi et al.
JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY (2022)
Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK
Tracey Weiss et al.
BMJ OPEN DIABETES RESEARCH & CARE (2022)
Meta-analysis: analysis of mechanistic pathways in the treatment of non-alcoholic steatohepatitis. Evidence from a Bayesian network meta-analysis
Mark D. Muthiah et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD)
Kenneth Cusi et al.
ENDOCRINE PRACTICE (2022)
Icosabutate: targeting metabolic and inflammatory pathways for the treatment of NASH
David A. Fraser et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2022)
Liver Stiffness on Magnetic Resonance Elastography and the MEFIB Index and Liver-Related Outcomes in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Individual Participants
Veeral Ajmera et al.
GASTROENTEROLOGY (2022)
Association of step counts over time with the risk of chronic disease in the All of Us Research Program
Hiral Master et al.
NATURE MEDICINE (2022)
Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease
Salvatore Petta et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
Enhanced Liver Fibrosis Score Can Be Used to Predict Liver-Related Events in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis
Vijay S. Are et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
Change in MRI-PDFF and Histologic Response in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis
Jonathan G. Stine et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
Liver Stiffness by Magnetic Resonance Elastography Predicts Future Cirrhosis, Decompensation, and Death in NAFLD
Tolga Gidener et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease
Ramy Younes et al.
JOURNAL OF HEPATOLOGY (2021)
Artificial Intelligence in NASH Histology: Human Teaches a Machine for the Machine to Help Humans
Mazen Noureddin
HEPATOLOGY (2021)
A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH
Amaro Taylor-Weiner et al.
HEPATOLOGY (2021)
ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials
Roberto A. Calle et al.
NATURE MEDICINE (2021)
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Sven M. Francque et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
Philip N. Newsome et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial
Rohit Loomba et al.
GASTROENTEROLOGY (2021)
Performance of the Enhanced Liver Fibrosis Test to Estimate Advanced Fibrosis Among Patients With Nonalcoholic Fatty Liver Disease
Zobair M. Younossi et al.
JAMA NETWORK OPEN (2021)
Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial
Samer Gawrieh et al.
HEPATOLOGY (2021)
Deuterium-Stabilized (R)-Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ Activity
Vincent Jacques et al.
HEPATOLOGY COMMUNICATIONS (2021)
Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis
Fernando Bril et al.
JOURNAL OF HEPATOLOGY (2020)
Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study
Stephen A. Harrison et al.
JOURNAL OF HEPATOLOGY (2020)
Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk
Mansoor Husain et al.
DIABETES OBESITY & METABOLISM (2020)
Tropifexor, a highly potent FXR agonist, produces robust and dose-dependent reductions in hepatic fat and serum alanine aminotransferase in patients with fibrotic NASH after 12 weeks of therapy: FLIGHT-FXR Part C interim results
K. J. Lucas et al.
DIGESTIVE AND LIVER DISEASE (2020)
Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension
Naga Chalasani et al.
GASTROENTEROLOGY (2020)
Complications After Percutaneous Ultrasound-Guided Liver Biopsy A Systematic Review and Meta-analysis of a Population of More Than 12,000 Patients From 51 Cohort Studies
Guo Tian et al.
JOURNAL OF ULTRASOUND IN MEDICINE (2020)
Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis
Bjorn Carlsson et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
Mark L. Hartman et al.
DIABETES CARE (2020)
Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
Jean-Francois Dufour et al.
GUT (2020)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Liver-Targeting Acetyl-CoA Carboxylase Inhibitor (PF-05221304): A Three-Part Randomized Phase 1 Study
Arthur Bergman et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2020)
Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials
Beth A. Davison et al.
JOURNAL OF HEPATOLOGY (2020)
MR elastography-based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: A multicenter study
Ma Ai Thanda Han et al.
LIVER INTERNATIONAL (2020)
Liver biopsy reliability in clinical trials: Thoughts from a liver pathologist
Elizabeth Matthews Brunt
JOURNAL OF HEPATOLOGY (2020)
Optimizing the Benefit/Risk of Acetyl-CoA Carboxylase Inhibitors through Liver Targeting
Kim Huard et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
Zobair Younossi et al.
HEPATOLOGY (2019)
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Stephen A. Harrison et al.
LANCET (2019)
Efficacy and adherence of glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes mellitus in real-life settings
B. Guerci et al.
DIABETES & METABOLISM (2019)
Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis
Rohit Loomba et al.
GASTROENTEROLOGY (2019)
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Zobair M. Younossi et al.
LANCET (2019)
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
Naga Chalasani et al.
HEPATOLOGY (2018)
Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease
Juan Pablo Arab et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 13 (2018)
The More Things Change, the More They Stay the Same: A Study to Evaluate Compliance With Inclusion and Assessment of Women and Minorities in Randomized Controlled Trials
Stacie E. Geller et al.
ACADEMIC MEDICINE (2018)
NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances
Mazen Noureddin et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2018)
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease
Rohit Loomba et al.
GASTROENTEROLOGY (2018)
Bile Acids and Nonalcoholic Fatty Liver Disease: Molecular Insights and Therapeutic Perspectives
Juan P. Arab et al.
HEPATOLOGY (2017)
Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes
Xueying Tan et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes
Zobair M. Younossi et al.
HEPATOLOGY (2016)
Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19
Mei Zhou et al.
CANCER RESEARCH (2014)
Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
Yoshio Sumida et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Utility of Magnetic Resonance Imaging Versus Histology for Quantifying Changes in Liver Fat in Nonalcoholic Fatty Liver Disease Trials
Mazen Noureddin et al.
HEPATOLOGY (2013)
Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome
Shin Yoshimoto et al.
NATURE (2013)
The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology
Naga Chalasani et al.
GASTROENTEROLOGY (2012)
Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients
Pierre Bedossa et al.
HEPATOLOGY (2012)
Effects of interventions on intra- and interobserver agreement on interpretation of nonalcoholic fatty liver disease histology
Samer Gawrieh et al.
ANNALS OF DIAGNOSTIC PATHOLOGY (2011)
Endpoints and clinical trial design for nonalcoholic steatohepatitis
Arun J. Sanyal et al.
HEPATOLOGY (2011)
Drug-Induced Acute Liver Failure: Results of a U.S. Multicenter, Prospective Study
Adrian Reuben et al.
HEPATOLOGY (2010)
FGF19-induced Hepatocyte Proliferation Is Mediated through FGFR4 Activation
Xinle Wu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Forced expression of hepatocyte-specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis
Xinqiang Huang et al.
MOLECULAR CARCINOGENESIS (2006)
A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience
L Goldkind et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2006)
Sampling variability of liver biopsy in nonalcoholic fatty liver disease
V Ratziu et al.
GASTROENTEROLOGY (2005)
Design and validation of a histological scoring system for nonalcoholic fatty liver disease
DE Kleiner et al.
HEPATOLOGY (2005)
Drug therapy: Thiazolidinediones
H Yki-Jarvinen
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
